Specialty pipeline perspectives – The upcoming wave of biosimilars

Evernorth anticipates a dramatic shift in inflammatory and oncology treatments over the next five years, with dozens of biosimilars in the pipeline.

March 26, 25

Biosimilars help lower costs and foster innovation in pharmacy benefits

By creating competition that can significantly reduce the prices of biologic medications, biosimilars create financial headroom for plan sponsors to offer coverage for innovative drug treatments.

September 30, 24

Express Scripts continues efforts to lower drug costs and ensure streamlined patient access to innovative biosimilars

August 23, 24

Leveraging biosimilars to drive savings and support patient access

By the end of 2024, 3 FDA-approved biosimilars to Stelara for patients living with inflammatory conditions will be closer to launch, enabling lower total drug spend.

July 01, 24

Evernorth chief bullish on driving affordability through biosimilars and access through guided care

May 08, 24

Outcomes 2024: How Evernorth manages the drug pipeline today and prepares for tomorrow

May 08, 24